EPS-201

N/A

Report date: 2022/05/16 11:29:40

Base Information

Drug NameEPS-201
Drug Alias NameEPS201
ClassificationBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsImmunostimulantsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsStomach NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEpsilogen Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEpsilogen Ltd
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A